ShapeShapeauthorShapecrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShaperssShape

MariCal Announces Strategic Alliance With ACD Pharmaceuticals AS

by the Fish Site Editor
06 September 2006, at 1:00am

US - MariCal Senior Vice President, William T. Thomas announced today the forming of a strategic alliance with ACD Pharmaceuticals AS for the exclusive representation of MariCals proprietary smoltification technology, the SuperSmolt Program, in Norway.

MariCal Annouces Strategic Alliance With ACD Pharaceuticals AS - US - MariCal Senior Vice President, William T. Thomas announced today the forming of a strategic alliance with ACD Pharmaceuticals AS for the exclusive representation of MariCals proprietary smoltification technology, the SuperSmolt® Program, in Norway.

MariCal, a privately-held aquatic life science biotechnology company headquartered in Portland, Maine, serves the global salmon aquaculture industry in solving aquatic health, nutrition and production issues.

ACD Pharmaceuticals is a Norwegian-based company owned by Nordly Holding AS, and with eight sister companies: Europharma AS; Europharma Nordic AS; Europharma Chile S.A.; Havsbrun Norge AS; Polarfeed Drift AS; Abelvr Marine AS and Prepare AS. The primary market focus of Nordly Holding AS and its subsidiaries is serving the salmon and marine aquaculture industry in Norway and Chile with vaccine distribution and fish health products, fish feed, and other services in the production of salmon/trout.

Mr. Thomas expressed, MariCal has successfully licensed its smoltification technology for application to more than 54 million smolt with the leading commercial salmon aquaculture companies in Norway, Scotland, Ireland, Chile and North America. This strategic alliance with ACD Pharmaceuticals, given their unique market position, exceptional reputation for product, technical support and customer service, will significantly strengthen our support to the growing demand for the SuperSmolt® Program in the Norwegian market.

The SuperSmolt® Program, a combined water treatment and specialty feed process is applied to juvenile salmonids pre-acclimating the fish to seawater while the fish remain in freshwater prior to their transfer as smolts to sea cages.

This strategic alliance allows us to extend our product and service offering to our customer base with the proven cutting-edge technology that the SuperSmolt®Program provides. This positively complements our position in the aquatic health products business, says Jim-Roger Nordly, CEO, Nordly Holding AS.

The SuperSmolt® Program is designed to lower production costs by increasing hatchery capacity, and through this, improve the efficacy of seawater production as well.

Arthur Lyngy, Manager of ACD Pharmaceuticals states, the SuperSmolt® Program is a production tool that will increase the capacity in existing hatcheries and can have a significant impact on addressing the current smolt shortage in Norway. The program creates a high quality smolt in a shorter time, compared to traditional production methods. This has a positive impact on transfer date and growth performance in the sea site. Were very excited about the potential of this Program and ACDs alliance with MariCal to represent their technology in Norway.

TheFishSite News Desk

the Fish Site Editor